AI in Life Sciences: Why Governance and Compliance Matter

The race to AI is shifting the technology landscape with boardrooms across the globe fighting to keep pace with every new wave of AI innovation. MedTech, biotech and pharma are no exception to this increasing pressure; the race to gain a competitive advantage is driving the C-level executives to make hard decisions. The shift to AI is no longer a future conversation, it is already happening across the enterprise. What was once limited to experimentation budgets is now becoming a core part of annual business strategy. In Life Sciences, the question is no longer whether to invest in AI, but whether organizations are mostly prepared to turn those investments into outcomes and lasting business value.

Three Segments. Different Pressures

AI is enabling new possibilities across Life Sciences, from accelerating drug discovery and optimizing clinical trials to enabling smarter medical devices and automating quality processes. But with that opportunity comes greater responsibility. Any AI-driven output that influences regulated decisions must meet strict compliance and documentation requirements under frameworks such as FDA 21 CFR Part 11, EU MDR, and ICH Q10, an area where many organizations are still addressing it.

PHARMA

CEO Lens

Under the requirements of 21 CFR Part 11 and GxP for every AI-assisted output which can either be related to adverse event detection, regulatory submission drafting, event detection all must fully traceable and audit-ready. Various regulatory bodies such as U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly want the organization's transparency around various model versions, validation process, training data lineage, and change history. The regulatory bodies want to follow the complete process not just AI-assisted output.

⚠ Every AI-influenced output is a documentation event.

BIOTECH

CTO Lens

Biotech companies usually prioritize advancements in science, while systems like ERP and data infrastructure take a back seat. Until commercialization becomes a priority for the Biotech companies. However, as Jade’s data and analytics practice has seen, AI built on disconnected LIMS, ERP, and supply chain systems rarely improve decision-making. On the other hand, they expose critical data gaps and operational inefficiencies, often surfacing just months before product launch. This hampers the speed, accuracy, and readiness of the complete system.

⚠ Isolated intelligence is not enterprise capability.

MEDTECH

CIO Lens

Evolving EU MDR and UDI requirements, the expectations for compliance and product oversight have become significantly higher. AI-enabled devices and post-market surveillance are now deeply embedded across the product lifecycle, making governance more critical than ever. Even small issues, such as unmonitored model drift or undocumented changes within the Quality Management System (QMS), can create serious compliance concerns and increase the risk of costly recalls.

⚠ Ungoverned AI in MedTech is a product recall risk.

Success Story

One of our Life Sciences clients spent nearly three years laying the foundation needed for successful AI adoption. They began with paper-based validation workflows and fragmented quality systems, then gradually modernized through digital validation, QMS integration, and stronger vendor compliance systems. Only after establishing such structure did they introduce AI/ML automation and continuous compliance monitoring.

The result was significant: 100% regulatory inspection compliance and a 90% improvement in overall process efficiency.

AI alone did not create that transformation. The governed, compliant, and connected foundation behind it did.

As AI Advances, So Must Your Partner Expectations

AI adoption in Life Sciences is entering a more mature phase. The use cases are real, early outcomes are encouraging, and the pressure to scale is growing. At the same time, the hesitation many organizations feel is understandable.

When AI initiatives slow down or fail in Life Sciences, the problem is rarely the model itself. More often, organizations have not fully connected AI outputs to validated business and quality workflows before deployment. Questions around ownership of IQ/OQ/PQ documentation become unclear as integration layers evolve, and teams most commonly lack alignment on what defines a successful AI-assisted batch release cycle in comparison to traditional processes.

These challenges usually do not surface during pilot programs. They emerge later, during the first FDA inspection or when an AI system signals a deviation without a clearly defined response process in place. That is why the most important conversation is no longer about what AI can do, but about who is accountable once AI becomes part of a validated and regulated environment.

CFO LENS

Across industries, only a small number of AI initiatives generate meaningful financial impact. In many cases, the challenge is not the technology itself, but the way AI programs are structured and executed. Success metrics are often unclear, timelines are disconnected from business priorities, and accountability fades once the initial implementation phase is complete.

Today’s CFOs are looking for more than innovation. They expect the same level of discipline applied to any major technology investment: clear ownership, measurable business outcomes, defined timelines, and partners who are equally accountable for delivering results.

The life sciences organizations pulling ahead aren’t those with the biggest AI budgets, they’re the ones making smarter bets: fewer initiatives, clear ownership, proven integration patterns, and accountability that extends beyond delivery.

The Right Partner Doesn’t Sell AI, They Share the Risk

Closing the gap isn’t about delivery alone, it starts with how the right partners design the engagement from day one.

AI + Human in the Loop

The real value of AI isn’t replacement, it’s augmentation. In GxP-critical workflows, the model surfaces insights, the human makes the decision, and the audit trail ensures full accountability.

Shared Risk. Outcome-Coupled.

Engagements tied to what truly moves the needle, submission cycle time, deviation reduction, batch release lead time. Where partner success is measured exactly like the client’s.

In regulated environments, this isn’t optional, it’s the difference between clearing validation and getting stuck in it.

The Jade Approach

Jade Global is a digital transformation partner with deep Life Sciences expertise. We are HIPAA certified, GxP-aware, and designed for pharma, biotech, and MedTech environments. We begin with your current architecture, compliance requirements, and enterprise platforms. AI serves as an integrated accelerator within your operations, rather than as a separate add-on.

We focus on four key practice areas for Life Sciences: ERP Modernization, GxP Validation integrated across QMS, LIMS, MES, and 3PLs, Enterprise AI Governance aligned with NIST AI RMF and ISO 42001, and Data Foundation engineering that removes upstream barriers before implementing AI.

We operate across:

Oracle · SAP · NetSuite · Salesforce · Boomi · Snowflake · ServiceNow

The goal isn't AI that looks good in a demo. It's AI you can stand behind in a regulatory review.

If that's the kind of engagement you're looking for, we'd like to talk, no deck, no pitch, just an honest conversation about where you are and where you want to go. Let's connect.

Subscribe to our Technology Insights

About the Author

Vinit Verma

Vice President - Integration & Data Analytics

Seasoned data and AI leader with over two decades of experience helping enterprises translate data, integration, and AI investments into measurable business outcomes. Leads Data and AI strategy with a strong focus on value realization, scalable execution, and enterprise-grade governance. Brings deep expertise across cloud data platforms, integrations, and applied AI, enabling organizations to move from experimentation to production with confidence. Recognized for building high-performing teams, strengthening strategic partnerships, and working closely with CXOs across high-tech, healthcare, and manufacturing industries.

About the Author

Srikrishna Seshadri

Director, Industry Verticals - HLS

Srikrishna is a Healthcare and Life Sciences transformation leader with 24+ years of experience in digital health, AI-led innovation, and enterprise modernization. He advises healthcare and life sciences organizations on AI transformation, AI strategy, and emerging technology adoption across the healthcare ecosystem.